预测HIV感染孕妇接受依非韦伦时双氢青蒿素-哌喹预防疟疾的最佳方案
结果显示每月2880 mg哌喹仅<1%孕妇达到保护性覆盖,而每周960 mg或每日低剂量(320或160 mg)可分别使34%和>96%孕妇达到保护性覆盖,且所有方案QTc延长风险均较低。
要点
- 每月DHA-PQ在依非韦伦治疗的HIV感染孕妇中哌喹暴露不足,保护性覆盖极低。
- 每日低剂量DHA-PQ(160或320 mg哌喹)可显著提高保护性覆盖比例。
- 所有评估方案QTc延长风险均较低,预测QTc增加≥30 msec者≤2%。
核心结论
- 对于接受依非韦伦的HIV感染孕妇,每日低剂量DHA-PQ方案预测比每月方案能更好预防寄生虫血症并降低毒性风险。
主要发现
- 哌喹清除率为4540 L/天。
- 每月DHA-PQ(2880 mg哌喹)时,<1%的孕妇达到保护性哌喹覆盖(浓度>10 ng/mL持续>95%预防期)。
- 每周960 mg哌喹方案使34%的孕妇达到保护性覆盖。
- 每日低剂量320或160 mg哌喹方案使>96%的孕妇达到保护性覆盖。
- 所有方案预测QTc增加≥30 msec的孕妇比例≤2%。
关键数值与推荐
- 保护性哌喹覆盖定义为维持浓度>10 ng/mL超过95%的化学预防期。
- 每月DHA-PQ剂量为2880 mg哌喹;每周方案为960 mg哌喹;每日低剂量方案为320或160 mg哌喹。
- 安全性阈值:预测QTc增加≥30 msec的孕妇比例≤2%。
临床怎么用
- 对于接受依非韦伦的HIV感染孕妇,可考虑每日低剂量DHA-PQ方案以改善疟疾预防效果并维持安全性。
局限性
- 研究基于药代动力学模型预测,需临床研究验证每日低剂量方案的实际疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A monthly treatment course of dihydroartemisinin-piperaquine (DHA-PQ) effectively prevents malaria during pregnancy. However, a drug-drug interaction pharmacokinetic (PK) study found that pregnant human immunodeficiency virus (HIV)-infected women receiving efavirenz-based antiretroviral therapy (ART) had markedly reduced piperaquine (PQ) exposure. This suggests the need for alternative DHA-PQ chemoprevention regimens in this population. METHODS: Eighty-three HIV-infected pregnant women who received monthly DHA-PQ and efavirenz contributed longitudinal PK and corrected QT interval (QTc) (n = 25) data. Population PK and PK-QTc models for PQ were developed to consider the benefits (protective PQ coverage) and risks (QTc prolongation) of alternative DHA-PQ chemoprevention regimens. Protective PQ coverage was defined as maintaining a concentration >10 ng/mL for >95% of the chemoprevention period. RESULTS: PQ clearance was 4540 L/day. With monthly DHA-PQ (2880 mg PQ), <1% of women achieved defined protective PQ coverage. Weekly (960 mg PQ) or low-dose daily (320 or 160 mg PQ) regimens achieved protective PQ coverage for 34% and >96% of women, respectively. All regimens were safe, with ≤2% of women predicted to have ≥30 msec QTc increase. CONCLUSIONS: For HIV-infected pregnant women receiving efavirenz, low daily DHA-PQ dosing was predicted to improve protection against parasitemia and reduce risk of toxicity compared to monthly dosing. CLINICAL TRIALS REGISTRATION: NCT02282293.
引用
- Wallender E, Vucicevic K, Jagannathan P, et al. Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz. J Infect Dis. 2018. PMID: 29272443. doi:10.1093/infdis/jix660
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。